I have thought about it. A few things hold me back. The lack of being able to get financing on better terms, the discrepancy in the male versus female response in the Univ of Minnesota study, the GMO thing seems a bit overdone in a population of smokers and the general overhang of being in an industry with a perception problem. I have almost pulled the trigger but maybe this is one where I'll just live with regret? Hard to say.
5.5 million units is equal to 275,000 packs. XXII paid $200,000 and $800K in stock for all the rights, interests, and manufacturing facilities in NASCO.
This is a steal, IMO. I would've been happy having paid $1M just for the MSA. Now they have NASCO's facilities and a veteran management team (former RJReynolds CEO & MPD) to boot.
University trials in collab. with Pfizer have evaluated and found XXII products to be effective in smoking cessation and quit rates (more than Nicotine Replacement Therapy and similar to Chaintix) , so we have the 1) tobacco side and the 2) technological/pharmacological side . Both avenues have dual-revenue opportunity